Last reviewed · How we verify
NCT06684184: BLINA-MG
Blinatumomab in Refractory Myasthenia Gravis (BLINA-MG)
Phase 2, PHASE3 trial testing Blinatumomab in Myasthaenia Gravis in 10 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Zhongming Qiu |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 30 November 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
Drugs / interventions tested
- Blinatumomab (blinatumomab) — full drug profile →
Conditions studied
- Myasthaenia Gravis — all drugs for Myasthaenia Gravis →
Sponsor
Zhongming Qiu — full company profile →
Who can join
Adults 18 to 75, any sex, with Myasthaenia Gravis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluating the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis and exploring the immunological mechanisms of Blinatumomab therapy in refractory myasthenia gravis. The main questions it aims to answer are: Will Blinatumomab improve the symptoms of participants? What medical problems do participants have when using Blinatumomab? Participants will: Continuous intravenous infusion of Blinatumomab for 5 days, pause for one week, and continue continuous intravenous infusion for 5 days Visit the clinic once every 1 month for checkups and tests Keep a diary of their symptoms
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06684184
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blinatumomab
Trials testing the same drug.
- NCT07192237 — Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Diseas · Phase 2 · not yet recruiting
- NCT07178912 — Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromoso · Phase 2 · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
Other recruiting trials for Myasthaenia Gravis
Currently open trials in the same condition.
- NCT06799247 — Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis · Phase 3 · recruiting
- NCT06765161 — Efgartigimod in IVIG Dependent Myasthenia Gravis Patients · Phase 3 · recruiting
- NCT06707727 — Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis · active not recruiting
- NCT06617741 — Myasthenia Gravis Foundation of America Global MG Patient Registry · recruiting
Other Zhongming Qiu trials
Trials by the same sponsor.
- NCT07355257 — TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM) · Phase 2, PHASE3 · not yet recruiting
- NCT06885762 — Efgartigimod for the Treatment of Guillain-Barré Syndrome · Phase 2, PHASE3 · not yet recruiting
- NCT06858722 — Ripertamab for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy · Phase 3 · not yet recruiting
- NCT06373042 — Tirofiban for Successful Endovascular Stroke Thrombectomy · Phase 2, PHASE3 · not yet recruiting
- NCT06388148 — Endovascular Treatment for eXtra-Large Ischemic Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06684184 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongming Qiu
- Last refreshed: 12 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06684184.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing